Supernus Pharmaceuticals, Inc. (SUPN) · Oct 26, 2026 · Other events

Supernus credit line ends ahead of Indivior merger

Credit line terminated — No borrowings or obligations outstanding at termination

Supernus terminated its unused UBS credit line as it prepares to close the Indivior merger and replace it with combined-company financing.

Supernus is preparing to combine with Indivior into a larger, diversified CNS drug company, with the merger now moving toward closing after Indivior shareholders approved it on October 15, 2026. This filing is merger-closing housekeeping, not a change to the operating story. Supernus terminated the UBS line on October 20 in anticipation of the transaction and the combined company’s planned new senior secured facility. 〔0〕

The termination carries no immediate balance-sheet hit. The facility was uncommitted and demand-based, and Supernus had no advances, letters of credit, borrowings, or other obligations outstanding when it was terminated; the related collateral pledge was also released. 〔1〕 This removes an unused standalone financing arrangement but does not provide new capital, reduce debt, or change earnings power.

Bottom line: The filing confirms financing cleanup ahead of the Indivior combination, with no economic surprise or new operating signal. Its real significance is that the merger-related transition is progressing toward a replacement credit facility.

What to watch next

Merger closing and new senior secured credit facility

Original filing on SEC EDGAR

More Supernus Pharmaceuticals, Inc. news

Supernus credit line ends ahead of Indivior merger | SUPN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.